



FOR IMMEDIATE RELEASE

Contact:

Peer M. Schatz
Inc.

Chief Financial Officer
QIAGEN N.V.
266

011 49 2103 892 702

e-mail: p.schatz@de.QIAGEN.com

Noonan/Russo Communications,

(212) 696-4455

Solene LeBouar (investor) ext.

Renee Solano (media) ext. 227

e-mail: news@noonanrusso.com

Erik Hornnaess Elected as Director of QIAGEN's Supervisory Board

Venlo, The Netherlands, June 29, 1998 — QIAGEN N.V. (Nasdaq:QGENF, Neuer Markt: QIA) today announced that Erik Hornnaess was elected to the Company's Board of Supervisory Directors.

Mr. Hornnaess former Area Vice-President of Abbott Diagnostic Division in Europe, Middle-East and Africa, to its Board of Directors at its annual shareholder meeting. Mr. Hornnaess also served as Vice-President of the European Diagnostic Manufacturers Association (EDMA) in Brussels from 1995 – 1997.

Mr. Hornnaess began his career in 1965 at Astra Pharmaceuticals, Sweden, where he held various management positions before joining Abbott Laboratories in 1979. He retired from Abbott Laboratories in March 1997, and currently serves as Chairman of the Board for AXIS Biochemicals ASA, Norway, and as non-executive Director of Alpharma Inc., USA (NYSE; ALO), APL Inc., USA, Radiometer A/S, Denmark, Shields Diagnostics Ltd., Scotland, and Orsys/Ilex Ltd., Israel. He serves on the Advisory Board of Techno Venture Management Medical Fund, Munich. Mr. Hornnaess also acts as a consultant to a number of US and European companies.

"Mr. Hornnaess's years of experience in the diagnostics industry will be a tremendous benefit to QIAGEN as his contribution will help us continue to build our significant opportunities as a supplier of our innovative enabling technologies and products to the emerging molecular diagnostics market," said QIAGEN's Chairman of the Supervisory Board, Professor Dr. Carsten P. Claussen. The Company's Chief Executive Officer, Metin Colpan added, "We believe that the addition of Mr. Hornnaess to the Board of Directors offers strong support for QIAGEN's growth in the new area of molecular diagnostics. This area is currently showing a high level of interest for our products and technologies since its success is dependent on factors including efficient nucleic acid separation and purification technologies to ensure reliable results.

We believe QIAGEN offers a comprehensive range of solutions for these needs and therefore is in a very attractive position to participate in their emergence and growth."

Mr. Hornnaess was nominated for election by the Supervisory Board. This nomination received shareholder approval today at the Company's Annual General Meeting of Shareholders.

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Australia and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation and purification of nucleic acids. The Company has developed a comprehensive portfolio of more than 260 proprietary, consumable products for nucleic acid separation and purification, nucleic acid amplification, as well as automated instrumentation and related services. QIAGEN's products are sold in more than 35 countries throughout the world to academic research markets and also to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid-based diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), and the Company's ability to identify and develop new products and to differentiate its products from competitors. For further information, refer to the discussion in reports that the Company has filed with the U.S. Securities and Exchange Commission (SEC).